Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qi Zhang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sarcoma-Derived Extracellular Vesicles: From Biology to Clinical Translation

    by Qi Zhang, Priya Dhawale, Patricia Sarchet, Hanxing Tong, Ali F. Usmani, Premanshu K. Singh, Shaurya Prakash, Yong Zhang, Raphael E. Pollock, Federica Calore

    Sarcomas constitute a heterogeneous group of rare mesenchymal malignancies encompassing soft tissue and bone sarcomas, whose histological and molecular diversity poses substantial challenges for early diagnosis, disease surveillance, and clinical management. Extracellular vesicles (EVs) are membrane-bound particles that mediate intercellular communication via delivery of bioactive cargo including proteins, nucleic acids, and lipids, and have emerged as promising analytes for minimally invasive liquid biopsy. While the biological functions and clinical value of EVs have been extensively characterized in common epithelial cancers, investigations focusing on sarcoma-derived EVs remain relatively limited and unevenly distributed across histological subtypes. Emerging evidence suggests that EV cargo can reflect molecular features of different sarcoma subtypes, including gene amplifications, fusion transcripts, miRNAs, lncRNAs, and tumor-associated proteins. This review provides an overview of current advances in sarcoma-derived EV research. We outline the classification of EV subtypes and their molecular cargo characteristics, with emphasis on features particularly relevant to sarcoma biology and biomarker development, as well as the technical principles, advantages, and limitations of EV isolation methodologies. We then focus on the roles of sarcoma-derived EVs in mediating tumor-host crosstalk, including facilitating the establishment of the pre-metastatic niche, promoting immunosuppression and immune evasion, and remodeling the tumor microenvironment. We further summarize emerging translational applications of sarcoma-derived EVs, covering their utility as circulating biomarkers for disease diagnosis, longitudinal monitoring, and treatment response assessment, as well as their potential as therapeutic targets for anti-tumor intervention. Where direct evidence in sarcoma remains limited, we distinguish findings established in sarcoma models from mechanisms extrapolated from other malignancies. Finally, we discuss current challenges to clinical translation, including small patient cohorts, lack of standardized technical protocols, and underrepresentation of rare histological subtypes. We propose that standardized EV isolation and characterization methods, larger collaborative datasets, and integration of multimodal liquid biopsy approaches will be important for advancing the clinical application of sarcoma-derived EVs and improving disease monitoring and patient management.

  • Open Access

    Tumor size and perineural invasion predict outcome of gastric high-grade neuroendocrine neoplasms

    by Qi Zhang, Hongshan Wang, Yanhong Xie, Suming Huang, Ke Chen, Botian Ye, Yupeng Yang, Jie Sun, Hongyong He, Fenglin Liu, et al.

    A new subcategory, grade 3 neuroendocrine tumors, is incorporated into the grading system of pancreatic neuroendocrine neoplasms in the 2017 WHO classification in order to differentiate grade 3 neuroendocrine tumors from neuroendocrine carcinomas. The 2019 WHO classification extends the concept of grade 3 neuroendocrine tumors to gastrointestinal high-grade neuroendocrine neoplasms. However, there is still limited study focusing on the gastric grade 3 neuroendocrine tumors and gastric neuroendocrine carcinomas. We retrospectively enrolled 151 gastric high-grade neuroendocrine neoplasms patients, who underwent radical resection from January 2007 to December 2015. Clinicopathologic and prognostic features were studied. The Surveillance, Epidemiology, and End Results (SEER) database was used to verify the prognostic determinants found in the Zhongshan cohort. Neuroendocrine carcinomas showed a higher Ki67 index and higher mitotic count than grade 3 neuroendocrine tumors. We identified 109 (72.2%) patients with neuroendocrine carcinomas, 12 (7.9%) patients with grade 3 neuroendocrine tumors, and 30 (19.9%) patients with mixed neuroendocrine-non-neuroendocrine neoplasms. Although neuroendocrine carcinomas demonstrated higher Ki67 index (P = 0.004) and mitoses (P = 0.001) than grade 3 neuroendocrine tumors, their prognosis after radical resection did not demonstrate significant differences (P = 0.709). Tumor size, perineural invasion, and TNM stage were independent prognostic factors of gastric high-grade neuroendocrine neoplasms. Abstract A new subcategory, grade 3 neuroendocrine tumors, is incorporated into the grading system of pancreatic neuroendocrine neoplasms in the 2017 WHO classification in order to differentiate grade 3 neuroendocrine tumors from neuroendocrine carcinomas. The 2019 WHO classification extends the concept of grade 3 neuroendocrine tumors to gastrointestinal high-grade neuroendocrine neoplasms. However, there is still limited study focusing on the gastric grade 3 neuroendocrine tumors and gastric neuroendocrine carcinomas. We retrospectively enrolled 151 gastric high-grade neuroendocrine neoplasms patients, who underwent radical resection from January 2007 to December 2015. Clinicopathologic and prognostic features were studied. The Surveillance, Epidemiology, and End Results (SEER) database was used to verify the prognostic determinants found in the Zhongshan cohort. Neuroendocrine carcinomas showed a higher Ki67 index and higher mitotic count than grade 3 neuroendocrine tumors. We identified 109 (72.2%) patients with neuroendocrine carcinomas, 12 (7.9%) patients with grade 3 neuroendocrine tumors, and 30 (19.9%) patients with mixed neuroendocrine-non-neuroendocrine neoplasms. Although neuroendocrine carcinomas demonstrated higher Ki67 index (P = 0.004) and mitoses (P = 0.001) than grade 3 neuroendocrine tumors, their prognosis after radical resection did not demonstrate significant differences (P = 0.709). Tumor size, perineural invasion, and TNM stage were independent prognostic factors of gastric high-grade neuroendocrine neoplasms.